Loading...

EXEL EXELIXIS INC Legal Disputes 8-K Filing

XLXS

XL

EXELIXIS INC

(EXEL)

2023 8-K

Show Summary

Show Summary

Financial Statements

Stock Award Program

Financial Results

Financial Results

Financial Results

Clinical Collaboration

Financial Results and Stock...

Annual Meeting Approval

Settlement and License Agre...

Complaint filed against Cip...

Financial Results Announcement

Departure of Directors

Financial Results Announcement

Earnings Release, Restructu...

Amendments to Change in Con...

Financial Results Announcement

Departure of Directors

Departure of Directors

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

Resignation of Director

Departure of Directors

External Links:

Exelixis, Inc. has made a Settlement and License Agreement with Teva Pharmaceuticals to resolve patent litigation. Teva will be licensed to market a generic version of Exelixis's CABOMETYX in the United States from January 1, 2031.

AI Assistant

EXELIXIS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.